Madrigal pharmaceuticals announces presentation of positive clinical data of resmetirom from open-label portion of ongoing phase 3 clinical trial maestro-nafld-1 at the international liver congress™ 2021

Conshohocken, pa., june 25, 2021 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), today announced the presentation of positive clinical data from the open-label portion of its ongoing phase 3 maestro-nafld-1 study of resmetirom at the european association for the study of the liver annual meeting, the international liver congress™ 2021, being held virtually, june 23-26, 2021. the data continue to position resmetirom as a promising treatment option for nonalcoholic steatohepatitis (nash) patients.
MDGL Ratings Summary
MDGL Quant Ranking